Abstracts tagged "interleukins (IL)"

Abstract Number: 2697 • 2018 ACR/ARHP Annual Meeting
Elevated Serum Interleukin-34 Levels Are Correlated with Interstitial Lung Disease in Systemic Sclerosis
Hiraku Suga¹, Ai Kuzumi¹, Yoshihide Asano¹, Ayumi Yoshizaki¹ and Shinichi Sato², ¹Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²The University of Tokyo, Department of Dermatology, Tokyo, Japan
Background/Purpose: Interleukin (IL)-34 is a hematopoietic cytokine, which promotes survival, proliferation, and differentiation of monocytes and macrophages. We investigated serum IL-34 levels in patients with…
Abstract Number: 991 • 2018 ACR/ARHP Annual Meeting
Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation
Anil K. Singh¹, Sabrina Fechtner¹, Mukesh Chourasia², Jerry Sicalo¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India
Background/Purpose: Interleukin-1β (IL-1β) and IL-1α are cytokines of IL-1 family that orchestrate acute and chronic inflammatory diseases. However, their distinct role or the extent of…
Abstract Number: 2801 • 2018 ACR/ARHP Annual Meeting
A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis
Kazuhiko Higashioka¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: A plethora of evidence from genome-wide association studies and relevant animal models implicates a pivotal role of T cells in the pathogenesis of rheumatoid…
Abstract Number: 1659 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
Roy Fleischmann¹, Vinod Chandran², Eric Lespessailles³, Julie Birt⁴, Olivier Benichou⁴, Janelle Erickson⁴ and Catherine Shuler⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Krembil Research Institute and University of Toronto, Toronto, ON, Canada, ³University of Orléans, Orléans, France, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements compared to placebo not only in disease activity but also in various…
Abstract Number: 2021 • 2018 ACR/ARHP Annual Meeting
Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis
Sandeep Kansurkar¹, Ankita Singh², Ramnath Misra³ and Amita Aggarwal³, ¹Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: IL-17 and IL-22 are important cytokines in pathogenesis of spondyloarthropathy. In an IL-23 or IL-22 over-expressing mouse model it was shown that enthesitis is…
Abstract Number: 2022 • 2018 ACR/ARHP Annual Meeting
Evidence of Inflammation Amplification By Interleukin-6 and Interleukin-17A in Synovial Compartment of Juvenile Idiopathic Arthritis – Enthesitis Related Arthritis
Rutviz Mistry¹, Sandeep Kumar¹, Sanjukta Majumder², Sandeep Kansurkar³, Amita Aggarwal¹ and Ramnath Misra¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: F759 mice with single amino-acid substitution in IL-6 receptor gp130 (Y759F) develops features of autoimmune disorders like arthritis, multiple sclerosis due to IL-17A and IL-6…
Abstract Number: 2411 • 2018 ACR/ARHP Annual Meeting
The Ovarian Reserve Measuring the Anti-Müllerian Hormone Is Not Diminished in Patients with Rheumatoid Arthritis Compared to the Healthy Population
Mireia López-Corbeto¹, Sara Marsal¹, Andrea Pluma², Sergio Martinez², Maria Lopez-Lasanta², Agusti Sellas-Fernandez², Juan José de Agustín² and Mireia Barcelo², ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is the most prevalent chronic inflammatory arthritis, affecting 0.5-1% worldwide population and predominates in females. Altered fertility has been reported due…
Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
Abstract Number: 2559 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Ana-Maria Orbai¹, Amanda M. Gellett², Lisa Kerr² and Arnaud Constantin³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Hopital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets IL-17A, was superior to placebo (PBO) at Week (Wk) 24 for treating PsA signs and…
Abstract Number: 2561 • 2018 ACR/ARHP Annual Meeting
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
Ana-Maria Orbai¹, Dafna D Gladman², Julie Birt³, Amanda M. Gellett³, Chen-Yen Lin³ and Tore Kvien⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Toronto, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements up to Week (Wk) 24 across several domains of PsA (including ACR20)…
Abstract Number: 2562 • 2018 ACR/ARHP Annual Meeting
Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
Ana-Maria Orbai¹, Iain B. McInnes², Laura C. Coates³, M. Elaine Husni⁴, Dafna D Gladman⁵, Laure Gossec⁶, Luminita Pricop⁷, Olivier Chambenoit⁸, Xiangyi Meng⁸ and Philip J. Mease⁹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Glasgow, Glasgow, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Cleveland Clinic, Cleveland, OH, ⁵Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada, ⁶Université Pierre et Marie Curie and Hôpital Pitié-Salpêtrière, Paris, France, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated efficacy for patients with psoriatic arthritis (PsA) in multiple phase 3 clinical…
Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Kim A Papp¹, Kenneth B. Gordon², Diamant Thaçi³, Akimichi Morita⁴, Melinda Gooderham⁵, Peter Foley^6,7,8, Ihab G. Girgis⁹, Sudeep Kundu⁹ and Subhashis Banerjee⁹, ¹Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Luebeck, Luebeck, Germany, ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵SKiN Centre for Dermatology, Queen’s University and Probity Medical Research, Peterborough, ON, Canada, ⁶The University of Melbourne, Melbourne, Australia, ⁷St Vincent’s Hospital Melbourne & Probity Medical Research, Melbourne, Australia, ⁸Skin & Cancer Foundation Inc, Melbourne, Australia, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…
Abstract Number: 2572 • 2018 ACR/ARHP Annual Meeting
Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
Luminita Pricop¹, Corine Gaillez², Gregory Ligozio³, Xuan Zhu³ and David James³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Subcutaneous secukinumab 150mg and 300mg are approved doses for the treatment of psoriatic arthritis (PsA) with the higher dose recommended for patients with anti-TNF inadequate…
Abstract Number: 142 • 2018 ACR/ARHP Annual Meeting
Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus
Xiao-Qing Liu¹, Na-Lin Lai², Yanan Duan¹, Junwei Chen¹, Xiao-Feng Li³ and Chong Gao⁴, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Regulatory T (Treg) cells, with the capacity to suppress immune responses, and effector T (Teff) cells, to promote inflammation, have been intensively studied in…
Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
Anthony Turkiewicz¹, Amanda M. Gellett², Lisa Kerr², Julie Birt² and Jordi Gratacos³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain
Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.